Search results
Showing 7801 to 7850 of 8236 results
This advice has been updated and replaced by NICE healthtech guidance 655.
EarlyCDT-Lung for cancer risk classification of indeterminate pulmonary nodules (MIB209)
This advice has been updated and replaced by NICE healthtech guidance 611.
FibroScan for assessing liver fibrosis and cirrhosis in primary care (MIB216)
This advice has been updated and replaced by NICE healthtech guidance 682.
Personal KinetiGraph for remote clinical management of Parkinson's disease (MIB258)
This advice has been updated and replaced by NICE healthtech guidance 657.
RapidAI for analysing CT/MRI brain scans in people with suspected acute stroke (MIB262)
This advice has been updated and replaced by NICE healthtech guidance 708.
The BCM – Body Composition Monitor for managing fluid in people having dialysis (MIB41)
This advice has been updated and replaced by NICE guidance HTG441
This advice has been updated and replaced by NICE healthtech guidance 553.
Point-of-care diagnostic testing in primary care for strep A infection in sore throat (MIB145)
This advice has been updated and replaced by NICE HealthTech guidance 531.
QAngio XA 3D/QFR imaging software for assessing coronary obstructions (MIB146)
This advice has been updated and replaced by NICE healthtech guidance 571.
Promonitor for monitoring response to biologics in rheumatoid arthritis (MIB126)
This advice has been replaced by NICE HealthTech guidance 521.
This advice has been updated and replaced by NICE healthtech guidance 730.
QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) (MIB318)
This advice has been updated and replaced by NICE healthtech guidance 729.
Point-of-care creatinine tests before contrast-enhanced imaging (MIB136)
This advice has been replaced by NICE HealthTech guidance 530.
We have moved Diagnostics guidance 32 to become HealthTech guidance 467. This is to better reflect the NICE HealthTech programme, which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Rapid tests for group A streptococcal infections in people with a sore throat (DG38)
We have moved Diagnostics guidance 38 to become HealthTech guidance 531. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 61 to become HealthTech guidance 730. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]
Discontinued Reference number: GID-TA10306
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]
Discontinued Reference number: GID-TA10334
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]
Discontinued Reference number: GID-TA10315
Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]
Discontinued Reference number: GID-TA10327
Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]
Discontinued Reference number: GID-TA10309
Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]
Discontinued Reference number: GID-TA10330
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued Reference number: GID-TA10295
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]
Discontinued Reference number: GID-TA10322
Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353
Discontinued Reference number: GID-TA10320
Discontinued Reference number: GID-TA10271
Guadecitabine for untreated acute myeloid leukaemia [ID1411]
Discontinued Reference number: GID-TA10325
Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (DG60)
We have moved Diagnostics guidance 60 to become HealthTech guidance 729. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (DG62)
We have moved Diagnostics guidance 62 to become HealthTech guidance 735. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This guidance has been updated and replaced by NICE healthtech guidance 598.
We have moved Diagnostics guidance 43 to become HealthTech guidance 571. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea (DG44)
We have moved Diagnostics guidance 44 to become HealthTech guidance 598. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
PredictSURE IBD and IBDX to guide treatment of Crohn's disease (DG45)
We have moved Diagnostics guidance 45 to become HealthTech guidance 610. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (DG46)
We have moved Diagnostics guidance 46 to become HealthTech guidance 611. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 47 to become HealthTech guidance 619. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (DG48)
We have moved Diagnostics guidance 48 to become HealthTech guidance 682. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
PLGF-based testing to help diagnose suspected preterm pre-eclampsia (DG49)
We have moved Diagnostics guidance 49 to become HealthTech guidance 630. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 5 to become HealthTech guidance 291. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
MRI-based technologies for assessing non-alcoholic fatty liver disease (DG50)
We have moved Diagnostics guidance 50 to become HealthTech guidance 655. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 51 to become HealthTech guidance 657. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 52 to become HealthTech guidance 677. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
MRI fusion biopsy systems for diagnosing prostate cancer (DG53)
We have moved Diagnostics guidance 53 to become HealthTech guidance 678. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 54 to become HealthTech guidance 680. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 55 to become HealthTech guidance 687. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 56 to become HealthTech guidance 690. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Artificial intelligence (AI)-derived software to help clinical decision making in stroke (DG57)
We have moved Diagnostics guidance 57 to become HealthTech guidance 708. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG58)
We have moved Diagnostics guidance 58 to become HealthTech guidance 719. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 59 to become HealthTech guidance 724. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (DG6)
We have moved Diagnostics guidance 6 to become HealthTech guidance 292. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 3 to become HealthTech guidance 281. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.